Funder: National Institutes of Health (NIH)
Due Dates: August 13, 2025 | December 18, 2025 | Final deadline November 24, 2025
Funding Amounts: Up to $500,000 direct costs per year (UG3 phase, up to 2 years); UH3 phase (up to 3 years) not limited but must reflect project needs.
Summary: Supports the phased development and clinical testing of neuromodulatory or neurophysiological devices as treatments for substance use disorders, aiming to advance devices toward FDA approval.
Key Information: Clinical trial optional; UG3/UH3 phased cooperative agreement; final application deadline is November 24, 2025.